STOCKHOLM, July 20, 2018 /PRNewswire/ -- Tobii AB today reported its results for the first quarter and first six months 2018.
Comment by Tobii's CEO Henrik Eskilsson:
"All three business units developed well in the second quarter. Tobii Dynavox more than doubled the number of units sold compared with the same period the previous year, Tobii Pro delivered yet another very strong quarter in terms of sales, and Tobii Tech advanced in both VR and PC gaming."
Second quarter April?June 2018
The Group's net sales increased to SEK 307 million (264), compared with the second quarter of 2017. Adjusted for currency effects, the increase was 15%.
Gross margin was 70% (71%).
The Group's operating loss amounted to SEK -59 million (-71). Tobii Dynavox contributed SEK 22 million (18) to earnings, Tobii Pro contributed SEK 1 million (-2), and investments in Tobii Tech had a negative impact of SEK -82 million (-87) on the Group's operating result.
Earnings per share amounted to SEK -0.41 (-0.75).
Significant events
Tobii Dynavox introduced Speech Case ? a product that converts the iPad into a complete voice and communication solution for people with disabilities.
Tobii Pro launched a new analysis tool for eye-tracking studies in VR environments based on a solution that was part of the Acuity acquisition earlier this year.
USB.org ap-proved a USB HID standard (Human Interface Device) for eye tracking that was developed by Tobii in collaboration with Microsoft, Intel and Eye Tech DS. Standardization fa-cilitates more extensive adoption of eye tracking in tablets and computers, as well as in software.
Microsoft launched an API (development interface) for eye tracking that makes it easier to integrate eye-tracking features in applications in Windows 10.
Conference call
Today at 2:00 p.m. CET, Tobii will host a conference call with web cast presentation for media, analyst and investors. Please find dial-in details on Tobii's website under Interim Report Q2 2018.
This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, on July 20, 2018, at 8:00 a.m. CET.
Contact:
Sara Hyléen, Director of Corporate Communications & Investor Relations, Tobii AB, phone: +46-709-16-16-41, email: [email protected]
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
To access the call by phone, please go to this registration link and you...
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...